NRSNNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NRSNW
NeuroSense Therapeutics Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026
$2.67−0.40 (-13.19%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -2175.0% | |
| Return on assets | – | – | -397.1% | |
| Current ratio | – | 6.38 | 0.31 | |
| Interest coverage | – | -2888.0× | – | |
| Diluted shares | – | – | 1M |
Where the cash went
Fiscal 2021 to 2025, five years combined
NeuroSense Therapeutics generated $35.32M from operations and spent $776.00K on capital expenditure, dividends and share buybacks. 16% of that went back into the business.
Generated
$35.32M
Used
$776.00K
Capital expenditure$127.00K16%Dividends$649.00K84%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$11.13M
- Cash generatingOperating cash flow above zero-$7.67M
- Return on assets improvedROA up on the prior year-320.6% → -243.2%
- Earnings backed by cashOperating cash flow above net income-$7.67M vs -$11.13M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.21 → 0.31
- No dilutionShare count did not rise1M → 1M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –